- Analysts have lowered the price target and downgraded Theravance Biopharma Inc TBPH after disappointing ulcerative colitis Phase 2 trial data.
- Related: Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study
- Cowen downgraded Theravance Biopharma to Market Perform from Outperform with a price target of $14, down from $42. Following the failure in ulcerative colitis, izencitinib "appears to have little future," analyst Marc Frahm tells investors.
- JAK inhibitors like izencitinib have mixed results in Crohn's disease, says Frahm, who sees little chance that Theravance's Phase 2 study is expected to succeed around year-end.
- SVB Leerink lowered the firm's price target to $29 from $37 and kept an Outperform rating.
- Analyst Geoffrey Porges believes this program appears to have no future and has no confidence that it will benefit Crohn's disease or the continuing follow-up observations in ulcerative colitis (UC).
- Needham cut the price target to $18 from $32, with a Buy rating. The UC outcome is a "clear disappointment," but there is no read-through to the ampreloxetine Phase 3 neurogenic orthostatic hypotension results expected in Q3.
- The current levels on Theravance offer favorable risk/reward ahead of the readout, analyst Joseph Stringer tells investors.
- H.C. Wainwright also lowered the price target to $21 from $32 and reiterated a Buy rating. While it seems less likely that Janssen will opt-in, even without the $200M milestone, Theravance's current cash should be sufficient until 2023, writes analyst Douglas Tsao.
- BofA lowered the price target to $14 from $20 and reiterated an Underperform rating.
- Analyst Tazeen Ahmad tells investors that the failure potentially reads through to the upcoming Crohn's disease readout.
- Baird slashed the price target to $10 from $20 and kept a Neutral rating.
- Analyst Brian Skorney said that the failed Phase 2 trial in ulcerative colitis is a death blow to the program.
- Price Action: TBPH shares are trading down 33.24% at $9.46 in the market on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
